BindingDB logo
myBDB logout

26 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
24411477 84 Carbamazepine derivatives with P2X4 receptor-blocking activity.EBI University of Bonn
24246730 34 Design and synthesis of potent and selective P2X3 receptor antagonists derived from PPADS as potential pain modulators.EBI Gwangju Institute of Science and Technology (GIST)
23510563 9 Synthesis and structure-activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists.EBI Gwangju Institute of Science and Technology
23121096 86 Ion channels as therapeutic targets: a drug discovery perspective.EBI Pfizer Inc.
16250663 8 Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.EBI University of Bonn
20045645 66 Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.EBI Roche Palo Alto
23075067 98 N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists.EBI University of Bonn
22370269 44 Discovery of P2X3 selective antagonists for the treatment of chronic pain.EBI AstraZeneca
17483457 58 A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.EBI Abbott Laboratories
17676725 6 Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist.EBI Institute of Science and Technology
11831909 4 Novel antagonists acting at the P2Y(1) purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques.EBI Universit£ Louis Pasteur
12213051 207 Purine and pyrimidine (P2) receptors as drug targets.EBI National Institute of Diabetes
15927468 3 Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.EBI Roche Palo Alto
15024037 49 [3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors.BDB Abbott Laboratories